Clinical and antibodies analysis of anti-GQ1b antibody syndrome: a case series of 15 patients

被引：0
作者：
Xiaohui Wu
Yuzhu Wang
Zhi-Qin Xi
机构：
[1] The First Affiliated Hospital,Department of Neurology
[2] Chongqing Medical University,undefined
来源：
Acta Neurologica Belgica | 2023年 / 123卷
关键词：
Anti-GQ1b antibody syndrome; Anti-ganglioside antibodies; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：839 / 847
页数：8
相关论文
共 50 条
  • [41] Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study
    Quaquarini, Erica
    Sottotetti, Federico
    Agustoni, Francesco
    Pozzi, Emma
    Malovini, Alberto
    Teragni, Cristina Maria
    Palumbo, Raffaella
    Saltalamacchia, Giuseppe
    Tagliaferri, Barbara
    Balletti, Emanuela
    Rinaldi, Pietro
    Canino, Costanza
    Pedrazzoli, Paolo
    Bernardo, Antonio
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (05):
  • [42] Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial
    Kappos, Ludwig
    Edan, Gilles
    Freedman, Mark S.
    Hartung, Hans-Peter
    Montalban, Xavier
    Barkhof, Frederik
    Koelbach, Ralf
    MacManus, David G.
    Wicklein, Eva-Maria
    JOURNAL OF NEUROLOGY, 2024, 271 (07) : 4599 - 4609
  • [43] Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
    Cao, Jun
    Wang, Biyun
    Zhang, Jian
    Tao, Zhonghua
    Wang, Leiping
    Hu, Xichun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [44] Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma
    Chen, Xinrui
    Qin, Yan
    Xue, Xuemin
    Xie, Zucheng
    Xie, Tongji
    Huang, Liling
    Zhu, Haohua
    Gao, Lina
    Li, Jiangtao
    Yang, Jianliang
    Gui, Lin
    Yang, Sheng
    Chen, Haizhu
    Feng, Xiaoli
    Shi, Yuankai
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [45] Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
    Pai, Sara, I
    Faivre, Sandrine
    Licitra, Lisa
    Machiels, Jean-Pascal
    Vermorken, Jan B.
    Bruzzi, Paolo
    Gruenwald, Viktor
    Giglio, Raul E.
    Leemans, C. Rene
    Seiwert, Tanguy Y.
    Soulieres, Denis
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [46] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
    Brunner, Andrew
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottman, Oliver
    Xu, Siyan
    Sun, Haiying
    Naidu, Purushotham
    Szpakowski, Sebastian
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael
    Wei, Andrew
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
  • [47] Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study
    Dousset, Lea
    Pacaud, Alize
    Barnetche, Thomas
    Kostine, Marie
    Dutriaux, Caroline
    Pham-Ledard, Anne
    Beylot-Barry, Marie
    Gerard, Emilie
    Prey, Sorilla
    Andreu, Nicolas
    Boniface, Katia
    Seneschal, Julien
    JAAD INTERNATIONAL, 2021, 5 : 112 - 120
  • [48] NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SURVIVAL AND CLINICAL ACTIVITY BY SUBGROUP ANALYSIS
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip D.
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Sznol, Mario
    Harbison, Christopher T.
    Kollia, Georgia D.
    Brahmer, Julie R.
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S152 - S152
  • [49] AN ANALYSIS OF THE RELATIONSHIP OF CLINICAL ACTIVITY TO BASELINE EGFR STATUS, PDL1 EXPRESSION AND PRIOR TREATMENT HISTORY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PD-L1 BLOCKADE WITH MPDL3280A (ANTI-PDL1)
    Horn, Leora
    Herbst, Roy S.
    Spigel, David
    Gettinger, Scott N.
    Gordon, Michael S.
    Hollebecque, Antoine
    Gandhi, Leena
    Felip, Enriqueta
    Heist, Rebecca
    Mokatrin, Ahmad
    Kowanetz, Marcin
    Waterkamp, Daniel
    Fine, Gregg
    Soria, Jean-Charles
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S364 - S364
  • [50] First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
    Pham, Toan
    Pereira, Lloyd
    Roth, Sara
    Galletta, Laura
    Link, Emma
    Akhurst, Tim
    Ben Solomon
    Michael, Michael
    Darcy, Phillip
    Sampurno, Shienny
    Heriot, Alexander
    Ramsay, Robert
    Desai, Jayesh
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
12345